Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.

European journal of cancer (Oxford, England : 1990) - 1 Jan 2023

Mueller Timothy, Laternser Sandra, Guerreiro Stücklin Ana S, Gerber Nicolas U, Mourabit Sulayman, Rizo Marion, Rushing Elisabeth J, Kottke Raimund, Grotzer Michael, Krayenbühl Niklaus, Nazarian Javad, Mueller Sabine

Abstract excerpt

BACKGROUND: Children diagnosed with diffuse midline gliomas (DMG) have an extremely poor overall survival: 9-12 months from diagnosis with currently no curative treatment options. Given DMG molecular heterogeneity, surgical biopsies are needed for molecular profiling and as part of enrolment into molecular-based and precision medicine type clinical interventions. In this study, we describe the results of real...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Stem Neoplasms
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Decision-Making

Share to Glioma

Share to Mutation

Source

Identifiers

PMID: 36455411
DOI: 10.1016/j.ejca.2022.10.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.PMID 36455411Read ↗

Clinical outcomes of stereotactic biopsy on children with pontine diffuse midline glioma.Semantic proximity Read ↗

Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic OpportunitiesSemantic proximity Read ↗

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategiesSemantic proximity Read ↗

A road map for the treatment of pediatric diffuse midline glioma.Semantic proximity Read ↗

Drug screening linked to molecular profiling identifies novel dependencies in patient-derived primary cultures of paediatric high grade glioma and DIPGSemantic proximity Read ↗

Therapeutic Targets in Diffuse Midline Gliomas—An Emerging LandscapeSemantic proximity Read ↗

Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry.Semantic proximity Read ↗

Current Clinical Practice About Pediatric Midline Gliomas in the Scope of Molecular Era.Semantic proximity Read ↗

Tumor extracellular vesicle RNA profiling predicts treatment response in pediatric diffuse midline gliomaSemantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid BiopsiesSemantic proximity Read ↗

MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.